Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Fuso Pharmaceutical Industries stock price, quote, forecast and news

4538.T
JP3823600006

Price

2,398.00 JPY
Today +/-
+0 JPY
Today %
+0 %
P

Fuso Pharmaceutical Industries Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fuso Pharmaceutical Industries, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fuso Pharmaceutical Industries from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fuso Pharmaceutical Industries’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fuso Pharmaceutical Industries. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fuso Pharmaceutical Industries’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fuso Pharmaceutical Industries’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fuso Pharmaceutical Industries’s growth potential.

Fuso Pharmaceutical Industries Revenue, EBIT and net profit per share

DateFuso Pharmaceutical Industries RevenueFuso Pharmaceutical Industries EBITFuso Pharmaceutical Industries Net Income
202455.41 B JPY1.96 B JPY1.38 B JPY
202351.02 B JPY2.21 B JPY1.61 B JPY
202249.63 B JPY1.92 B JPY1.48 B JPY
202149.25 B JPY2.35 B JPY1.61 B JPY
202046.9 B JPY1.01 B JPY707 M JPY
201946.07 B JPY1.26 B JPY894 M JPY
201845.9 B JPY798 M JPY970 M JPY
201746.78 B JPY656 M JPY861 M JPY
201645.75 B JPY296 M JPY10 M JPY
201547.04 B JPY796 M JPY340 M JPY
201449.1 B JPY2.8 B JPY1.98 B JPY
201348.61 B JPY3.82 B JPY4.87 B JPY
201244.36 B JPY480 M JPY372 M JPY
201147.47 B JPY1.84 B JPY1.14 B JPY
201046.56 B JPY321 M JPY518 M JPY
200945.9 B JPY302 M JPY-931 M JPY
200843.99 B JPY-502 M JPY107 M JPY
200743.17 B JPY540 M JPY-2.04 B JPY
200642.66 B JPY787 M JPY-1.93 B JPY
200541.92 B JPY1.3 B JPY566 M JPY

Fuso Pharmaceutical Industries Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B JPY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B JPY)EBIT (B JPY)EBIT MARGIN (%)NET INCOME (B JPY)NET INCOME GROWTH (%)DIV. (JPY)DIV. GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
45.0745.2445.3244.2341.9341.3541.9242.6643.1743.9945.946.5647.4744.3648.6149.147.0445.7546.7845.946.0746.949.2549.6351.0255.41
-0.380.19-2.42-5.20-1.371.371.781.181.914.341.441.95-6.559.591.00-4.19-2.742.25-1.890.381.795.010.772.798.61
36.4936.3934.4333.8931.5932.9332.5432.0430.3328.5830.1829.5428.3727.4931.5129.9027.6327.4328.3228.9129.1527.2928.6526.9926.9324.98
16.4516.4615.6114.9913.2513.6213.6413.6713.0912.5713.8513.7513.4712.1915.3214.681312.5513.2513.2713.4312.814.1113.413.7413.84
2.852.921.481.24-0.091.121.30.790.54-0.50.30.321.840.483.822.80.80.30.660.81.261.012.351.922.211.96
6.336.463.262.80-0.202.713.111.841.25-1.140.660.693.871.087.855.701.690.651.401.742.742.154.773.884.323.54
0.740.970.41-0.36-1.10.540.57-1.93-2.040.11-0.930.521.140.374.871.980.340.010.860.970.890.711.611.481.611.38
-31.80-57.49-186.71205.29-149.274.81-440.995.60-105.25-970.09-155.64120.85-67.481,209.41-59.37-82.82-97.068,510.0012.66-7.84-20.92127.30-7.728.23-14.21
--------------------------
--------------------------
99999999999999999.059.048.998.858.788.778.778.778.778.61
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Fuso Pharmaceutical Industries Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Fuso Pharmaceutical Industries is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M JPY)RECEIVABLES (M JPY)OTHER REC. (M JPY)INVENTORIES (M JPY)OTHER CURRENT LIAB. (M JPY)CURRENT ASSETS (M JPY)TANGIBLE ASSETS (M JPY)LONG-T. INVEST. (M JPY)LONG-T. REC. (M JPY)INTANGIBLE ASSETS (M JPY)GOODWILL (M JPY)OTHER NON-CURRENT ASSETS (M JPY)NON-CURRENT ASSETS (M JPY)TOTAL ASSETS (M JPY)LIABILITIESCOMMON STOCK (M JPY)ADDITIONAL PAID-IN CAPITAL (M JPY)RETAINED EARNINGS (M JPY)OTHER EQUITY (M JPY)UNREAL. GAINS/LOSSES (M JPY)EQUITY (M JPY)LIABILITIES (M JPY)PROVISIONS (M JPY)OTHER SHORT-TERM LIAB. (M JPY)SHORT-TERM DEBTS (M JPY)LONG-TERM DEBT PORTION (M JPY)SHORT-TERM REC. (M JPY)LONG-T. LIAB. (M JPY)DEFERRED TAXES (M JPY)OTHER LIAB. (M JPY)LONG-T. LIABILITIES (M JPY)DEBT (M JPY)TOTAL CAPITAL (M JPY)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Fuso Pharmaceutical Industries provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Fuso Pharmaceutical Industries's financial health and stability.

Assets

Fuso Pharmaceutical Industries's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Fuso Pharmaceutical Industries must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Fuso Pharmaceutical Industries after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Fuso Pharmaceutical Industries's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B JPY)DEPRECIATION (B JPY)DEFERRED TAXES (M JPY)CHANGES IN WORKING CAPITAL (B JPY)NON-CASH ITEM (B JPY)PAID INTEREST (M JPY)PAID TAXES (B JPY)NET CASH FLOW FROM OPERATING ACTIVITIES (B JPY)CAPITAL EXPENDITURES (M JPY)CASH FLOW FROM INVESTING ACTIVITIES (B JPY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)INTEREST INCOME AND EXPENSES (M JPY)NET DEBT CHANGE (B JPY)NET CHANGE IN EQUITY (M JPY)CASH FLOW FROM FINANCING ACTIVITIES (B JPY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (JPY)TOTAL DIVIDENDS PAID (M JPY)NET CHANGE IN CASH FLOW (B JPY)FREE CASH FLOW (M JPY)SHARE-BASED COMPENSATION (M JPY)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
1.890.93-0.39-1.542.381.09-2.05-1.410.05-0.150.570.980.016.242.650.650.121.061.361.261.042.351.912.21
2.672.662.582.672.552.1422.132.232.152.212.091.891.751.881.911.5121.921.972.382.412.562.49
000000000000000000000000
-1.4-1.47-1.390.58-2.18-2.510.640.890.38-1.31-1.123.06-1.49-2.52-1.89-0.770.45-0.87-1.33-1.112.35-1.48-1.02-1.78
0.640.581.451.05-2.040.452.770.01-0.670.50.520.810.48-2.210.250.140.04-0.32-0.53-0.06-0.04-0.050.05-0.06
493403370366306310259255317302304302247261248222225225217229234195176166
1.591.060.580.40.091.30.280.290.030.060.030.050.040.022.470.32-0.310.10.580.350.370.190.980.24
3.82.72.252.760.711.183.351.611.991.182.196.940.893.262.891.942.121.881.422.055.733.233.52.85
-1,251-2,661-1,789-1,494-656-942-2,074-1,057-2,463-2,390-1,171-1,015-1,206-1,928-1,655-2,538-5,312-1,838-1,717-2,318-2,502-1,210-1,487-1,574
-1.28-2.83-1.73-2.162.18-0.51-2.74-0.56-0.59-2.76-1.43-1.34-1.382.42-1.78-2.89-5.34-0.79-0.98-2.37-1.49-0.98-1.55-1.37
-0.03-0.170.06-0.672.830.44-0.670.51.88-0.37-0.25-0.33-0.184.34-0.12-0.35-0.021.050.73-0.051.020.23-0.070.2
000000000000000000000000
-0.49-0.33-0.040.290.18-1.45-0.60.55-1.150.62-0.33-4.241.49-0.28-1.6-0.223.06-0.151.210.41-1.18-1.92-1.14-0.28
-1-2-13-72-838-367-32-33-18-20-7-8-3-5-14-10-7-282-427-6-2-4-2-3
-1.44-1.28-1-0.54-1.22-2.37-1.18-0.03-1.710.06-0.88-4.790.94-0.83-2.43-0.962.33-1.150.07-0.31-1.8-2.45-1.67-0.81
-------------2.00-1.00--1.00-3.00-1.00-3.00-15.00-2.00-1.00-1.00-1.00
-944-944-945-756-566-551-545-544-543-542-541-542-542-542-812-722-721-717-706-700-613-525-525-525
1.09-1.4-0.480.061.67-1.69-0.561.03-0.31-1.53-0.120.80.454.84-1.32-1.9-0.89-0.060.51-0.632.44-0.190.270.67
2,551434601,262542361,278557-477-1,2071,0145,927-3211,3301,234-595-3,19438-296-2663,2242,0202,0101,279
000000000000000000000000

Fuso Pharmaceutical Industries stock margins

The Fuso Pharmaceutical Industries margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fuso Pharmaceutical Industries. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fuso Pharmaceutical Industries.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fuso Pharmaceutical Industries's sales revenue. A higher gross margin percentage indicates that the Fuso Pharmaceutical Industries retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fuso Pharmaceutical Industries's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fuso Pharmaceutical Industries's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fuso Pharmaceutical Industries's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fuso Pharmaceutical Industries. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fuso Pharmaceutical Industries's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fuso Pharmaceutical Industries Margin History

Fuso Pharmaceutical Industries Gross marginFuso Pharmaceutical Industries Profit marginFuso Pharmaceutical Industries EBIT marginFuso Pharmaceutical Industries Profit margin
202424.98 %3.54 %2.49 %
202326.93 %4.32 %3.15 %
202226.99 %3.88 %2.99 %
202128.65 %4.77 %3.26 %
202027.29 %2.15 %1.51 %
201929.15 %2.74 %1.94 %
201828.91 %1.74 %2.11 %
201728.32 %1.4 %1.84 %
201627.43 %0.65 %0.02 %
201527.63 %1.69 %0.72 %
201429.9 %5.7 %4.03 %
201331.51 %7.85 %10.02 %
201227.49 %1.08 %0.84 %
201128.37 %3.87 %2.41 %
201029.54 %0.69 %1.11 %
200930.18 %0.66 %-2.03 %
200828.58 %-1.14 %0.24 %
200730.33 %1.25 %-4.72 %
200632.04 %1.84 %-4.52 %
200532.54 %3.11 %1.35 %

Fuso Pharmaceutical Industries Stock Sales Revenue, EBIT, Earnings per Share

The Fuso Pharmaceutical Industries earnings per share therefore indicates how much revenue Fuso Pharmaceutical Industries has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fuso Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fuso Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fuso Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fuso Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fuso Pharmaceutical Industries Revenue, EBIT and net profit per share

DateFuso Pharmaceutical Industries Sales per ShareFuso Pharmaceutical Industries EBIT per shareFuso Pharmaceutical Industries Earnings per Share
20246,434.77 JPY228.09 JPY159.92 JPY
20235,816.28 JPY251.51 JPY182.99 JPY
20225,657.78 JPY219.33 JPY169.05 JPY
20215,613.54 JPY267.96 JPY183.16 JPY
20205,344.87 JPY115.1 JPY80.57 JPY
20195,249.52 JPY143.67 JPY101.86 JPY
20185,186.38 JPY90.17 JPY109.6 JPY
20175,206.61 JPY73.01 JPY95.83 JPY
20165,058.75 JPY32.73 JPY1.11 JPY
20155,199.65 JPY87.98 JPY37.58 JPY
20145,455.33 JPY310.78 JPY219.89 JPY
20135,401.33 JPY424 JPY541.22 JPY
20124,928.67 JPY53.33 JPY41.33 JPY
20115,274.33 JPY204.33 JPY127.11 JPY
20105,173.33 JPY35.67 JPY57.56 JPY
20095,100.11 JPY33.56 JPY-103.44 JPY
20084,887.89 JPY-55.78 JPY11.89 JPY
20074,796.33 JPY60 JPY-226.44 JPY
20064,740.44 JPY87.44 JPY-214.44 JPY
20054,657.67 JPY144.67 JPY62.89 JPY

Fuso Pharmaceutical Industries business model

Fuso Pharmaceutical Industries is one of the most popular companies on Eulerpool.com.

Fuso Pharmaceutical Industries historical P/E ratio, EBIT, and P/S ratio.

Fuso Pharmaceutical Industries shares outstanding

The number of shares was Fuso Pharmaceutical Industries in 2023 — This indicates how many shares 8.771 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fuso Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fuso Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fuso Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fuso Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fuso Pharmaceutical Industries Stock splits

In Fuso Pharmaceutical Industries's history, there have been no stock splits.

Fuso Pharmaceutical Industries dividend history and estimates

In 2023, Fuso Pharmaceutical Industries paid a dividend amounting to 75 JPY. Dividend means that Fuso Pharmaceutical Industries distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Fuso Pharmaceutical Industries provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Fuso Pharmaceutical Industries’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Fuso Pharmaceutical Industries's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Fuso Pharmaceutical Industries Dividend History

DateFuso Pharmaceutical Industries Dividend
202475 JPY
202375 JPY
202260 JPY
202160 JPY
202060 JPY
201970 JPY
201880 JPY
201780 JPY
201680 JPY
201580 JPY
201480 JPY
201370 JPY
201260 JPY
201160 JPY
201060 JPY
200960 JPY
200860 JPY
200760 JPY
200660 JPY
200590 JPY

Fuso Pharmaceutical Industries dividend payout ratio

In 2023, Fuso Pharmaceutical Industries had a payout ratio of 47.57%. The payout ratio indicates the percentage of the company's profits that Fuso Pharmaceutical Industries distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Fuso Pharmaceutical Industries represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Fuso Pharmaceutical Industries could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Fuso Pharmaceutical Industries's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Fuso Pharmaceutical Industries Payout Ratio History

DateFuso Pharmaceutical Industries Payout ratio
202438.61 %
202347.57 %
202235.49 %
202132.76 %
202074.47 %
201968.72 %
201872.99 %
201783.49 %
20167,235.3 %
2015212.87 %
201436.38 %
201312.93 %
2012145.17 %
201147.2 %
2010104.26 %
2009-58 %
2008505.05 %
2007-26.5 %
2006-27.98 %
2005143.13 %
Unfortunately, there are currently no price targets and forecasts available for Fuso Pharmaceutical Industries.

Fuso Pharmaceutical Industries list of shareholders

%
Name
Stocks
Change
Date
7.00 % Budoh Kyowakai Association598,000-8,0009/30/2023
5.29 % Shikishima Shinko Company452,00009/30/2023
3.65 % Sumitomo Mitsui Trust Bank, Limited311,700-65,3009/15/2023
3.26 % Sumitomo Mitsui Banking Corp278,8518513/15/2024
3.01 % Fuso Pharmaceutical Industries Ltd. Employees257,0004,0009/30/2023
2.62 % MUFG Bank, Ltd.224,000-121,0009/30/2023
2.45 % Nomura Asset Management Co., Ltd.209,1971,3003/31/2024
2.35 % SMBC Nikko Securities Inc.200,700200,7003/15/2024
2.08 % Toda (Mikio)178,000178,0009/30/2023
2.05 % Dimensional Fund Advisors, L.P.175,39903/31/2024
1
2
3
4
...
5

Most common questions regarding Fuso Pharmaceutical Industries

What is the P/E ratio of Fuso Pharmaceutical Industries 2024?

The Fuso Pharmaceutical Industries P/E ratio is 15.

What is the P/S ratio of Fuso Pharmaceutical Industries 2024?

The Fuso Pharmaceutical Industries P/S ratio is 0.37.

What is the AlleAktien quality score of Fuso Pharmaceutical Industries?

The AlleAktien quality score for Fuso Pharmaceutical Industries is 2/10.

What is the revenue of Fuso Pharmaceutical Industries 2024?

The Fuso Pharmaceutical Industries revenue is 55.41 B JPY.

How high is the profit of Fuso Pharmaceutical Industries 2024?

The Fuso Pharmaceutical Industries profit is 1.38 B JPY.

What is the business model of Fuso Pharmaceutical Industries

No history available for Fuso Pharmaceutical Industries.

What is the Fuso Pharmaceutical Industries dividend?

Fuso Pharmaceutical Industries pays a dividend of 60 JPY distributed over payouts per year.

How often does Fuso Pharmaceutical Industries pay dividends?

The dividend cannot currently be calculated for Fuso Pharmaceutical Industries or the company does not pay out a dividend.

What is the Fuso Pharmaceutical Industries ISIN?

The ISIN of Fuso Pharmaceutical Industries is JP3823600006.

What is the Fuso Pharmaceutical Industries ticker?

The ticker of Fuso Pharmaceutical Industries is 4538.T.

How much dividend does Fuso Pharmaceutical Industries pay?

Over the past 12 months, Fuso Pharmaceutical Industries paid a dividend of 75 JPY . This corresponds to a dividend yield of about 3.13 %. For the coming 12 months, Fuso Pharmaceutical Industries is expected to pay a dividend of 75 JPY.

What is the dividend yield of Fuso Pharmaceutical Industries?

The current dividend yield of Fuso Pharmaceutical Industries is 3.13 %.

When does Fuso Pharmaceutical Industries pay dividends?

Fuso Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Fuso Pharmaceutical Industries?

Fuso Pharmaceutical Industries paid dividends every year for the past 20 years.

What is the dividend of Fuso Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 75 JPY are expected. This corresponds to a dividend yield of 3.13 %.

In which sector is Fuso Pharmaceutical Industries located?

Fuso Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fuso Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fuso Pharmaceutical Industries from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Fuso Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Fuso Pharmaceutical Industries in the year 2023?

In the year 2023, Fuso Pharmaceutical Industries distributed 75 JPY as dividends.

In which currency does Fuso Pharmaceutical Industries pay out the dividend?

The dividends of Fuso Pharmaceutical Industries are distributed in JPY.

All fundamentals about Fuso Pharmaceutical Industries

Our stock analysis for Fuso Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fuso Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.